Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2018)
23 slides from Vita Life Sciences's shareholder meeting presentation, May 25, 2018
Slide 1: Welcome - 2018 Annual General Meeting
For personal use only WELCOME 2018 ANNUAL GENERAL MEETING 25 May 2018
Slide 2: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer
Slide 3: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer
Slide 4: Market Presence: Countries
MARKET PRESENCE: 7 COUNTRIES For personal use only
Slide 5: Business Overview
BUSINESS OVERVIEW For personal use only • Australian & Asia Pacific based pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements • 3 major consumer retail brands • 750-800 registered SKUs of vitamins and supp
Slide 6: FY 2017 Group Snapshot
FY 2017 GROUP SNAPSHOT For personal use only Revenue EBIT* EPS* (A$m) (cps) (A$m) 40 6 7 35 6 30 4 5 25 4 20 3 6.06 15 2 4.89 10 2 5 1 0 0 0 2017 2016 2017 2016 2017 2016 * Including share options expense of $0.9m HIGHLIGHTS • Group sales of $37.7 million, marginally lower (0.2%) than the previous c
Slide 7: FY 2017 Group Snapshot (continued)
FY 2017 GROUP SNAPSHOT For personal use only HIGHLIGHTS (continued) • Cash conversion rate of 100% • Returned $2.3m to shareholders via dividends and share buyback • Final fully franked dividend of 2.25c; taking full year dividend of 3.75c CHALLENGES • Period of transformational change and stability
Slide 8: Full Year 2017 Results
FULL YEAR 2017 RESULTS For personal use only 2017 revenue by geography 2016 revenue by geography Other Other Asia Asia 7% Australia 6% Australia Singapore Singapore 41% 17% 41% 17% Asia Asia 59% 59% Malaysia 35% Malaysia 36% Total revenue: $37.7m Total revenue: $37.8m
Slide 9: Australia
Revenue (A$m) AUSTRALIA For personal use only 16.0 2017 Sales: $15.6m (2016: $15.6m) 12.0 H2 H2 • Revenue base business was sustained in a highly competitive Australian market 8.0 • Export sales from Australia to China; lower than expected 4.0 H1 H1 • Gross margins remained strong - 2017 2016 2017 E
Slide 10: Malaysia
Revenue (A$m) MALAYSIA 16 For personal use only 12 2017 Sales $13.2m (2016: $13.5m) H2 H2 8 • Revenue base increased by 6.7% in local currency but it was impacted by weaker Malaysian ringgit (2017 average A$1: MYR 3.2971 [2016: MYR 3.0072]) 4 • Increase in revenue of 98% in local currency from the H
Slide 11: Singapore
Revenue (A$m) SINGAPORE For personal use only 6 2017 Sales $6.5m (2016: $6.5m) H2 H2 • Revenue base business was sustained in a highly competitive market 4 through a revised brand strategy • HOG brand recorded strong growth of 119% (PCP) 2 H1 H1 • VH brand recorded a slight decline during this perio
Slide 12: Other Asia
OTHER ASIA For personal use only 2017 Sales $2.5m (2016: $2.2m) • Revenue growth of 15% (PCP) Revenue (A$m) • Stronger sales were recorded for Vietnam and Thailand • Vietnam continues to perform to expectation and is expected to grow faster into FY2018 • Indonesia and Thailand remains challenging an
Slide 13: Strategic Priorities & Outlook
STRATEGIC PRIORITIES & OUTLOOK For personal use only • 2018 will be the second of a three year strategic plan set to grow long term revenues • Increased advertising and promotional investment in core markets • Increasing export sales to China utilising strategic partnerships from within Australia •
Slide 14: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer
Slide 15: Ordinary Resolutions
ORDINARY RESOLUTIONS For personal use only 1. Remuneration Report 2. Re-election of Director - Mr Jonathan Tooth 3. Share Buy-Back 4. Long Term Incentive Plan- Mr Andrew O’Keefe
Slide 16: Proxy Results
For personal use only PROXY PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN DISCRETION TOTALS 1) Adoption of the Remuneration Report 3,624,316 42,833 1,744,025 13,664,727 19,075,901 2) Re-election of Director 3,975,744 29,700 6,250 15,064,957 19,076,651 (Mr Jonathan Tooth) 3) Share Buy-Back 4,002,811
Slide 17: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer
Slide 18: Thank You
For personal use only THANK YOU Contact: Telephone: +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/ 102 Bath Road, Kirrawee, NSW 2232
Slide 19: Appendix
For personal use only APPENDIX
Slide 20: Appendix – Profit & Loss
For personal use only APPENDIX 1 – PROFIT & LOSS Full year ended Dec 2017 2016 $m $m Revenue 37.7 37.8 EBITDA 5.0 6.0 EBIT 4.7 5.7 Profit before tax 4.7 5.6 Profit after tax 2.8 3.3 EPS (Basic – cents/ share) 5.21 6.06 Dividend (cents / share) 3.75 3.75
Slide 21: Appendix – Balance Sheet
For personal use only APPENDIX 2 – BALANCE SHEET Balance Sheet as at Dec 2017 Dec 2016 $m $m Current assets 22.3 21.7 Non-current assets 10.6 10.6 Total assets 32.9 32.3 Current liabilities 6.0 6.8 Non-current liabilities 2.1 2.3 Total Liabilities 8.1 9.1 Net Assets 24.8 23.2
Slide 22: Appendix – Cash Flow
For personal use only APPENDIX 3 – CASH FLOW Cash Flow for the year ended 2017 2016 $m $m Receipts from customers 40.8 41.6 Payments to suppliers and employees 34.8 36.2 Gross operating cash flow 6.0 5.4 Adjusted EBITDA (excluding share options expense) 6.0 6.0 Gross operating cash flow / EBITDA 100
Slide 23: Disclaimer
For personal use only DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any of